Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Opthea ( (AU:OPT) ).
Opthea has reported a quarter marked by operational simplification and strategic repositioning, including its delisting from Nasdaq, completion of a strategic review, and a sharper focus on developing OPT-302 for the rare lung disease lymphangioleiomyomatosis. The company’s cash position improved to US$22.2 million at 31 December 2025, aided by a US$7.2 million R&D tax incentive, and it significantly reduced operating cash outflows while incurring modest R&D and administration costs tied partly to staff terminations. With a streamlined cost base and clearer capital position, Opthea plans to advance feasibility work on nebulised delivery of OPT-302 for LAM, evaluate prudent capital deployment, and seek reinstatement of trading in its shares on the ASX in the first half of 2026, developments closely watched by investors amid the ongoing suspension of its securities.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.56 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is an Australia-based biotechnology company focused on developing biologic therapies, including its lead candidate OPT-302, for serious diseases. The company operates in the biopharmaceutical sector, with a current strategic emphasis on exploring OPT-302 as a potential treatment for lymphangioleiomyomatosis (LAM).
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
See more insights into OPT stock on TipRanks’ Stock Analysis page.